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term toxicity and efficacy data are clearly crucial and will be 
reported in due course. 
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Purpose/Objective: To evaluate the feasibility and toxicity 
of hypofractionated stereotactic body radiation therapy 
(SBRT) with volumetric modulated arc therapy (VMAT) and 
flattening filter-free (FFF) beams. 
Materials and Methods: A prospective designated phase I-II 
study was approved by our institutional review and ethics 
board (started in April 2013). Inclusion criteria were 
histologically proven prostate adenocarcinoma, Gleason Score 
6–7, clinical stage T1b–T2b, prostate-specific antigen (PSA) ≤ 
20 ng/mL, prostate volume ≤ 60 cc, no previous surgery, no 
malignant tumours in the previous 5 years, IPSS 0–7 Neo-
adjuvant/concomitant hormonal-therapy was prescribed 
according to risk classification. Image Guided RT with Cone 
Beam CT (with or without fiducial markers) is mandatory. 
Urinary catheter was needed to plan and deliver radiation in 
order to maintain bladder volume stable during treatment. 
SBRT was delivered at a prescribed planning target volume 
(PTV) dose of 35 Gy in five fractions in 5 alternative days 
using the TrueBeam with RapidArc VMAT, with 6 MV FFF 
photons. CTCAE v3.0 morbidity scores were used to assess 
toxicities. 
Results: A total of 11 patients have been recruited to date. 
Mean age of the patients was 71.2 years (range: 64–76 yr). 
Pathology centralized Gleason score was 6 in 6 patients and 7 
(3+4) in another five patients. Mean PSA was 9 ng/mL (range: 
0.03–17 ng/mL). According to D'Amico risk classification, 6/11 
patients were low-risk and 5/11 were intermediate risk. Mean 
prostate volume was 38.3 cc. All patients completed the 
treatment as programmed in 2 weeks and tolerated the 
treatment well. One haematuria related to renal colic and 
hypertensive crisis were observed in two different patients at 
the first session. Evaluating patients in a time period ranging 
from 3 to 18 months, no toxicity greater than grade 2 was 
observed. . Acute Toxicities were as follow: Rectum G0: 2/11 
cases (18.2%); G1: 5/11 (45.6%); G2: 4/11 (36.4%). Genito-
urinary: G1: 8/11 (72,3%); G2: 3/11 (27,3%). At 3 months 
follow-up toxicities were as follow: Rectum G0: 5/11 cases 
(45.6%); G1: 6/11 (54,5 %); G2: 1/11 (9.1%). Genito-urinary: 
G0: 4/11 (36.4%), G1: 6/11 (54.5 %); G2: 1/11 (9.1%).Test 
between average total IPSS at pre-entry when compared with 
1-month and 3-month evaluations showed a non-significant 
increase in mean value from 4 to 6. Biochemical response 
was seen at 3 month of follow-up with mean value of 2.1 
ng/ml (range from 0.03 to 5.89). 
Conclusions: Early findings indicate that SBRT with VMAT and 
FFF beams for low–intermediate-risk prostate cancer 
delivered in five fractions is feasible and well tolerated in 
selected patients. Long-term follow-up is needed for 
assessment of late toxicity and outcomes. 
  
EP-1259   
Endorectal ballooning with posterior rectal wall dose 
constraint in prostate cancer radiotherapy 
K. Park1, S. You1, J.Y. Lee1, J. Cha1 
1Yonsei Univer. Wonju College of Med, Radiation Oncology, 
Wonju Kangwondo, Korea Republic of  
 
Purpose/Objective: Anterior rectal wall (ARW) receives 
inevitable high radiation dose in prostate cancer 
radiotherapy. The rectum-protective effect of endorectal 
ballooning (ERB) was assessed in terms of separate anatomic 
categorization focusing ARW and its dose distribution.  
Materials and Methods: Between Aug 2012 and Mar 2014, 
thirty one patients received curative tomotherapy for 
prostate cancer treatment. All treatment sessions were 
performed by intensity-modulated simultaneous integrated 
boost method to each target volume with customized 60 mL 
air balloon inserted into the rectum. The prescription dose 
was 70.0 Gy, 60.2 Gy, and 50.4 Gy to each planning target 
volume (PTV) for prostate gland (PG), seminal vesicles, and 
elective pelvic lymph node area with 28 fractionations, 
respectively. The ARW and posterior rectal wall (PRW) were 
contoured separately with 5 mm-thickness through the ERB-
inflated rectum area. In thirteen patients (49.1%, Group 1), 
PRW dose was restricted to maximum 40 Gy without ARW 
dose fixing. The other 18 patients (58.1%, Group 2) were 
treated by conventional dose constraint without additional 
dose condition to PRW area.  
Results: All patients completed their scheduled radiotherapy 
courses. The PG PTV dose distribution did not differ between 
the two groups (p = 0.694). The median PG PTV volume was 
46.5 mL (range, 15.9 - 127.2 mL), and its mean dose, D1%, V95% 
was 70.8 ± 0.65 Gy, 72.1 Gy, 69.8%, respectively. The 
overlapped volume between PG PTV and ARW was 13.4 mL. 
The mean dose and conformity index (V95%/VPG PTV) did not 
show significant difference between the two groups 
(p=0.405). The average dose, D1%, D50%, D70%, V20Gy, and V40Gy 
for ARW were not significantly different between the two 
groups. However, V60Gy had a tendency to be higher in Group 
1 (p=0.087). Acute rectal and urinary toxicities occurred in 4 
patients (12.9%) and 23 patients (74.2%), respectively, 
without Grade 3 or higher toxicity in both groups. No 
significant difference in rectal (p>0.999) and urinary 
(p=0.592) toxicity was showed between the two groups. 
Conclusions: Proper dose constraint to PRW showed tolerable 
acute toxicity profile without compromising PG PTV 
conformity despite the risk of high dose distribution to ARW 
area. However, radiobiological analysis may be required 
together with dose-volume approach in this relative 
conservative dose constraint condition. 
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